Francesmary Modugno

ORCID: 0000-0003-0637-1534 · 143 papers in corpus
observational 2024
·doi:10.1158/1055-9965.27029569.v1

Supplementary Table 3 shows the associations between folate intake (dietary, supplemental, total) and ovarian cancer by endometriosis status, and by histological subtype (endometrioid/clear cell cancers and high grade serous cancers).

observational 2024
·doi:10.1158/1055-9965.27029569

Supplementary Table 3 shows the associations between folate intake (dietary, supplemental, total) and ovarian cancer by endometriosis status, and by histological subtype (endometrioid/clear cell cancers and high grade serous cancers).

observational 2024
·doi:10.1158/1055-9965.27029566.v1

Supplementary Table 4 shows the association between glycemic index, glycemic load, grain intake and risk of ovarian cancer for women with and without endometriosis.

observational 2024
·doi:10.1158/1055-9965.27029566

Supplementary Table 4 shows the association between glycemic index, glycemic load, grain intake and risk of ovarian cancer for women with and without endometriosis.

2024
·doi:10.1158/1055-9965.27029563

Supplementary Table 5 shows the results from the different Mendelian randomization methods investigating the association between genetically predicted folate and risk of ovarian cancer, by endometriosis status

2024
·doi:10.1158/1055-9965.27029563.v1

Supplementary Table 5 shows the results from the different Mendelian randomization methods investigating the association between genetically predicted folate and risk of ovarian cancer, by endometriosis status

observational 2024
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology ·doi:10.1158/1055-9965.EPI-24-0187

BACKGROUND: Cancers of ductal origin often express glycoprotein mucin 1 (MUC1), also known as CA15.3, with higher levels leading to poor prognosis. Conversely, anti-MUC1 antibodies develop in some patients, leading to better prognosis. We s…

observational 2023
Journal of the National Cancer Institute ·doi:10.1093/jnci/djad137

Generally, risk stratification models for cancer use effect estimates from risk/protective factor analyses that have not assessed potential interactions between these exposures. We have developed a 4-criterion framework for assessing intera…

observational 2023
JAMA network open ·doi:10.1001/jamanetworkopen.2023.0666

IMPORTANCE: Frequent aspirin use is associated with reduced ovarian cancer risk, but it is unknown whether genetic factors modify this association. Understanding effect modifiers is important given that any use of aspirin for ovarian cancer…

lab-animal 2023
·doi:10.1158/0008-5472.c.6514212

AbstractOvarian clear cell carcinoma (OCCC) is a deadly and treatment-resistant cancer, which arises within the unique microenvironment of endometriosis. In this study, we identified a subset of endometriosis-derived mesenchymal stem cells …

lab-animal 2023
·doi:10.1158/0008-5472.c.6514212.v1

AbstractOvarian clear cell carcinoma (OCCC) is a deadly and treatment-resistant cancer, which arises within the unique microenvironment of endometriosis. In this study, we identified a subset of endometriosis-derived mesenchymal stem cells …

2023
·doi:10.1158/1055-9965.c.6695948

AbstractBackground:Although folate intake has not been associated with an increased risk of ovarian cancer overall, studies of other cancer types have suggested that high folate intake may promote carcinogenesis in precancerous lesions. Wom…

2023
·doi:10.1158/1055-9965.c.6695948.v1

AbstractBackground:Although folate intake has not been associated with an increased risk of ovarian cancer overall, studies of other cancer types have suggested that high folate intake may promote carcinogenesis in precancerous lesions. Wom…

2023
·doi:10.1158/1055-9965.c.6695948.v2

AbstractBackground:Although folate intake has not been associated with an increased risk of ovarian cancer overall, studies of other cancer types have suggested that high folate intake may promote carcinogenesis in precancerous lesions. Wom…

observational 2023
·doi:10.1158/1055-9965.c.6515916

AbstractBackground: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian canc…

observational 2023
·doi:10.1158/1055-9965.c.6515916.v1

AbstractBackground: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian canc…

observational 2023
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology ·doi:10.1158/1055-9965.EPI-23-0121

BACKGROUND: Although folate intake has not been associated with an increased risk of ovarian cancer overall, studies of other cancer types have suggested that high folate intake may promote carcinogenesis in precancerous lesions. Women with…

observational 2023
Gynecologic Oncology ·doi:10.1016/j.ygyno.2022.10.018

OBJECTIVE: The presence of macroscopic residual disease after primary cytoreductive surgery (PCS) is an important factor influencing survival for patients with high-grade serous ovarian cancer (HGSC). More research is needed to identify fac…

other 2023
Journal of the National Cancer Institute ·doi:10.1093/jnci/djad011

BACKGROUND: The role of ovulation in epithelial ovarian cancer (EOC) is supported by the consistent protective effects of parity and oral contraceptive use. Whether these factors protect through anovulation alone remains unclear. We explore…

observational 2023
The journal of pathology. Clinical research ·doi:10.1002/cjp2.311

Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carci…

2023
·doi:10.1158/0008-5472.22432671.v1

Supplementary figures and table

2023
·doi:10.1158/0008-5472.22432671

Supplementary figures and table

observational 2023
·doi:10.1158/1055-9965.23516099

Supplementary Figure 1 shows a flowchart of exclusions to obtain the study population, with the number of cases and controls eligible for the analysis.

observational 2023
·doi:10.1158/1055-9965.23814285.v1

Supplementary Figure 1 shows a flowchart of exclusions to obtain the study population, with the number of cases and controls eligible for the analysis.

observational 2023
·doi:10.1158/1055-9965.23516099.v1

Supplementary Figure 1 shows a flowchart of exclusions to obtain the study population, with the number of cases and controls eligible for the analysis.